easysite
You are here > Services > Research and Development > Our current areas of Research > Cardiology Studies
.

Cardiology Studies

Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes (PROMINENT)

Study area: Cardiology

Aim: The PROMINENT Study is researching a potential new medication (study drug) called pemafibrate to find out if it is safe and can help prevent heart attacks and other heart-related problems among people with type 2 diabetes and elevated triglycerides. It will also look at how the study drug affects triglyceride levels.

Who can participate: You may be able to take part if you:

  •  have a diagnosis of type 2 diabetes for 12 weeks or longer
  • are a woman 55 years of age or more, a man 50 years of age or more, or are 18 years of age or more with systemic atherosclerosis (also called artery disease, which is a hardening or narrowing of the arteries)
  • have been told you have moderately high triglyceride levels. Please ask your doctor if you are not sure.

Senior-Rita

More information about this study can be found here: https://clinicaltrials.gov/ct2/show/NCT03052036


The dal-GenE trial

Evaluating the effects of study drug Dalcetrapib on reducing repeat cardiovascular events in a genetically defined population whom have recently had a heart attack.

Study area: Cardiology

Background: Dalcetrapib is an investigational drug that has been tested in several large clinical trials for its effect on reducing cardiovascular risk in those who have had a heart attack. Results to date have demonstrated that treatment with Dalcetrapib may significantly benefit people who have a particular gene (AA) variant. 

Aim: To test the effect of Dalcetrapib only in patients with the AA variant to confirm these findings of cardiovascular benefit.

Who can participate:Anyone aged 45 years and over who has had a heart attack within the last 12 weeks. Exclusions apply; please contact us for more information.

If you would like any further information on the following studies, and to find out if you are eligible please contact:

 

Address: R&D office, C254, West Wing, Broomfield Hospital, Court Road, Chelmsford, Essex, CM1 7ET 

Telephone01245 515136
Email: Research@meht.nhs.uk